ArticlePLoS neglected tropical diseases2026
Impact of praziquantel treatment and early reinfection patterns in a mixed Schistosoma mansoni and Schistosoma haematobium infection focus in the Democratic Republic of Congo.
Article in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the impact of single versus mixed Schistosoma infections on the efficacy of PZQ treatment as well as on the dynamics of reinfection after treatment.
methodsWe followed 388 randomly selected residents of a village co‑endemic for Schistosoma haematobium and S. mansoni, screening them for Schistosoma infection every three weeks across a nine‑week period. Kato-Katz stool examination was used to detect eggs of S. mansoni and urine filtration to detect eggs of S. haematobium. At every visit, those who were positive for schistosomiasis were treated with 40mg/kg praziquantel. Treatment outcomes (cure rate (CR), egg reduction rate (ERR), cumulative cure rate (CCR) and cumulative egg reduction rate (CERR)) and reinfection rates were compared between age groups, sex and pre-treatment co-infection status using McNemar and Wilcoxon tests.
resultsBaseline infection prevalence was similar for S. mansoni (60.8%) and S. haematobium (60.3%), with 36.6% of mixed S. haematobium-S. mansoni infection. Infection intensity was higher in mixed compared to single infection (200.7 versus 70 epg for S. mansoni, p < 0.001; 29 versus 9.6 ep10mL for S. haematobium, p < 0.001). After one praziquantel treatment, CR of 62.7% and 94.6%, with ERR of 97.5% and 96.5%, were found for S. haematobium and S. mansoni, respectively. After 3 rounds of praziquantel treatment, CCR of 75% and 93.7%, with CERR of 95.6% and 97.5%, were recorded for S. haematobium and S. mansoni, respectively. In addition, treatment efficacy was significantly higher in single than in mixed infections (CR = 76.7% versus 58%, p = 0.01; ERR = 90.2% versus 96.5%, p < 0.001; CCR = 76.7% versus 58%, p = 0.01; CERR = 90.2% versus 96.5%, p < 0.001), and in older than in younger (<16 years) age groups. No significant associations were found between (co-)infection status and reinfection rate.
conclusionOur results show that pre-treatment co-infection status can affect schistosomiasis treatment outcomes for S. haematobium but does not affect the post-treatment reinfection. These results could help in tailoring control activities in co-endemic areas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.